Doubly-robust estimator of the difference in restricted mean times lost with competing risks data

Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models

(2021) Sarwar I. Mozumder et al.   BMC Medical Research Methodology

Estimation and modeling of the restricted mean time lost in the presence of competing risks

(2021) Sarah C. Conner et al.   STATISTICS IN MEDICINE

Fine‐Gray subdistribution hazard models to simultaneously estimate the absolute risk of different event types: Cumulative total failure probability may exceed 1

(2021) Peter C. Austin et al.   STATISTICS IN MEDICINE

Estimating heterogeneous survival treatment effect in observational data using machine learning

(2021) Liangyuan Hu et al.   STATISTICS IN MEDICINE

On the empirical choice of the time window for restricted mean survival time

(2020) Lu Tian et al.   BIOMETRICS

G-computation, propensity score-based methods, and targeted maximum likelihood estimator for causal inference with different covariates sets: a comparative simulation study

(2020) Arthur Chatton et al.   Scientific Reports

Using simulation studies to evaluate statistical methods

(2019) Tim P. Morris et al.   STATISTICS IN MEDICINE

Adjusted restricted mean survival times in observational studies

(2019) Sarah C. Conner et al.   STATISTICS IN MEDICINE

One‐step targeted maximum likelihood estimation for time‐to‐event outcomes

(2019) Weixin Cai et al.   BIOMETRICS

RESOLVING AN APPARENT PARADOX IN DOUBLY ROBUST ESTIMATORS

(2018) Alexander P Keil et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?

(2018) Theodore Karrison et al.   Clinical Trials

Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards

(2018) Iván Díaz et al.   LIFETIME DATA ANALYSIS

Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks

(2018) Lihui Zhao et al.   JAMA Cardiology

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment

(2018) I R Weir et al.   ANNALS OF ONCOLOGY

Balancing Covariates via Propensity Score Weighting

(2017) Fan Li et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms

(2017) Judith J. Lok et al.   LIFETIME DATA ANALYSIS

Modeling restricted mean survival time under general censoring mechanisms

(2017) Xin Wang et al.   LIFETIME DATA ANALYSIS

Causal inference in survival analysis using pseudo-observations

(2017) Per K. Andersen et al.   STATISTICS IN MEDICINE

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research

(2016) Ina Jazić et al.   JNCI-Journal of the National Cancer Institute

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis

(2016) Peter C. Austin   STATISTICS IN MEDICINE

Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research

(2016) Ina Jazić et al.   JNCI-Journal of the National Cancer Institute

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions

(2013) Tyler J. VanderWeele et al.   ANNALS OF INTERNAL MEDICINE

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Pseudo-observations for competing risks with covariate dependent censoring

(2013) Nadine Binder et al.   LIFETIME DATA ANALYSIS

Decomposition of number of life years lost according to causes of death

(2013) P. K. Andersen   STATISTICS IN MEDICINE

Double-Robust Semiparametric Estimator for Differences in Restricted Mean Lifetimes in Observational Studies

(2012) Min Zhang et al.   BIOMETRICS

Doubly Robust Estimation of Causal Effects

(2011) Michele Jonsson Funk et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

SAS and R functions to compute pseudo-values for censored data regression

(2008) John P. Klein et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

On pseudo-values for regression analysis in competing risks models

(2008) Frederik Graw et al.   LIFETIME DATA ANALYSIS